Akebia Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
AKBA$0.54+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Years Ended December 31, | ||
|---|---|---|
| (dollars in thousands, except per share amounts) | 2024 | 2023 |
| Revenues: | ||
| Product revenue, net | $152,180 | $170,301 |
| License, collaboration and other revenue | 8,000 | 24,322 |
| Total revenues | 160,180 | 194,623 |
| Cost of goods sold: | ||
| Cost of product and other revenue | 27,135 | 38,107 |
| Amortization of intangible asset | 36,042 | 36,042 |
| Total cost of goods sold | 63,177 | 74,149 |
| Operating expenses: | ||
| Research and development | 37,652 | 63,079 |
| Selling, general and administrative | 106,545 | 100,233 |
| License | 3,220 | 3,237 |
| Restructuring | 58 | 181 |
| Total operating expenses | 147,475 | 166,730 |
| Loss from operations | (50,472) | (46,256) |
| Other income (expense): | ||
| Interest expense | (18,185) | (6,032) |
| Other income | 94 | 887 |
| Change in fair value of warrant liability | (330) | — |
| Loss on extinguishment of debt | (517) | — |
| Loss on termination of lease | — | (524) |
| Net loss before income taxes | (69,410) | (51,925) |
| Net loss | $(69,410) | $(51,925) |
| Comprehensive loss | $(69,410) | $(51,925) |
| Net loss per share: | ||
| Basic and diluted | $(0.33) | $(0.28) |
| Weighted average number of common shares outstanding: | ||
| Basic and diluted | 210,946,658 | 187,465,448 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.